{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:12:35Z","timestamp":1790003555291,"version":"4.0.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004189","name":"Max-Planck-Gesellschaft","doi-asserted-by":"publisher","award":["2012\/2016"],"award-info":[{"award-number":["2012\/2016"]}],"id":[{"id":"10.13039\/501100004189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","award":["PUE 2016"],"award-info":[{"award-number":["PUE 2016"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005363","name":"Universidad de Buenos Aires","doi-asserted-by":"publisher","award":["20020130100427BA"],"award-info":[{"award-number":["20020130100427BA"]}],"id":[{"id":"10.13039\/501100005363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003074","name":"Ministry of Science, Technology and Productive Innovation, Argentina | Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["PICT2014-3634,PICT2016-1620"],"award-info":[{"award-number":["PICT2014-3634,PICT2016-1620"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondo de Convergencia Estructural del Mercosur COF 03\/11"},{"name":"Bunge and Born Foundation Argentina, Fellowship"},{"name":"Instituto Nacional del Cancer (INC), Argentina. Fellowship."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Renal cell carcinoma (RCC) is the major cause of death among patients with von Hippel-Lindau (VHL) disease. Resistance to therapies targeting tumor angiogenesis opens the question about the underlying mechanisms. Previously we have described that RWDD3 or RSUME (RWD domain-containing protein SUMO Enhancer) sumoylates and binds VHL protein and negatively regulates HIF degradation, leading to xenograft RCC tumor growth in mice. In this study, we performed a bioinformatics analysis in a ccRCC dataset showing an association of RSUME levels with VHL mutations and tumor progression, and we demonstrate the molecular mechanism by which RSUME regulates the pathologic angiogenic phenotype of VHL missense mutations. We report that VHL mutants fail to downregulate RSUME protein levels accounting for the increased RSUME expression found in RCC tumors. Furthermore, we prove that targeting RSUME in RCC cell line clones carrying missense VHL mutants results in decreased early tumor angiogenesis. The mechanism we describe is that RSUME sumoylates VHL mutants and beyond its sumoylation capacity, interacts with Type 2 VHL mutants, reduces HIF-2\u03b1-VHL mutants binding, and negatively regulates the assembly of the Type 2 VHL, Elongins and Cullins (ECV) complex. Altogether these results show RSUME involvement in VHL mutants deregulation that leads to the angiogenic phenotype of RCC tumors.<\/jats:p>","DOI":"10.1038\/s41419-019-1507-3","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T21:19:45Z","timestamp":1553030385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME"],"prefix":"10.1038","volume":"10","author":[{"given":"Lucas","family":"Tedesco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Elguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Gonilski","family":"Pacin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Senin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora","family":"Pollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio A.","family":"Garcia Marchi\u00f1ena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto M.","family":"Jurado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Isola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J.","family":"Labanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Palazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Yankilevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Fuertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7697-8107","authenticated-orcid":false,"given":"Eduardo","family":"Arzt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"key":"1507_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/ejhg.2010.175","volume":"19","author":"ER Maher","year":"2011","unstructured":"Maher, E. R., Neumann, H. P. & Richard, S. von Hippel-Lindau disease: a clinical and scientific review. Eur. J. Hum. Genet. 19, 617\u2013623 (2011).","journal-title":"Eur. J. Hum. Genet."},{"key":"1507_CR2","first-page":"521","volume":"31","author":"M Nordstrom-O\u2019Brien","year":"2010","unstructured":"Nordstrom-O\u2019Brien, M. et al. Genetic analysis of von Hippel-Lindau disease. Hum. Mutat. 31, 521\u2013537 (2010).","journal-title":"Hum. Mutat."},{"key":"1507_CR3","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm0895-822","volume":"1","author":"O Iliopoulos","year":"1995","unstructured":"Iliopoulos, O., Kibel, A., Gray, S. & Kaelin, W. G. Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1, 822\u2013826 (1995).","journal-title":"Nat. Med."},{"key":"1507_CR4","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1172\/JCI67230","volume":"123","author":"GL Semenza","year":"2013","unstructured":"Semenza, G. L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest. 123, 3664\u20133671 (2013).","journal-title":"J. Clin. Invest."},{"key":"1507_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc3183","volume":"12","author":"B Keith","year":"2011","unstructured":"Keith, B., Johnson, R. S. & Simon, M. C. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12, 9\u201322 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"1507_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/onc.2017.338","volume":"37","author":"D Tarade","year":"2018","unstructured":"Tarade, D. & Ohh, M. The HIF and other quandaries in VHL disease. Oncogene 37, 139\u2013147 (2018).","journal-title":"Oncogene"},{"key":"1507_CR7","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.18632\/oncotarget.2593","volume":"5","author":"H Hu","year":"2014","unstructured":"Hu, H. et al. Hypoxia-inducible factors enhance glutamate signaling in cancer cells. Oncotarget 5, 8853\u20138868 (2014).","journal-title":"Oncotarget"},{"key":"1507_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10059-010-0067-2","volume":"29","author":"A Loboda","year":"2010","unstructured":"Loboda, A., Jozkowicz, A. & Dulak, J. HIF-1 and HIF-2 transcription factors\u2013similar but not identical. Mol. Cells 29, 435\u2013442 (2010).","journal-title":"Mol. Cells"},{"key":"1507_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature19795","volume":"539","author":"H Cho","year":"2016","unstructured":"Cho, H. et al. On-target efficacy of a HIF-2alpha antagonist in preclinical kidney cancer models. Nature 539, 107\u2013111 (2016).","journal-title":"Nature"},{"key":"1507_CR10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","volume":"120","author":"R Roskoski Jr.","year":"2017","unstructured":"Roskoski, R. Jr. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. Pharmacol. Res. 120, 116\u2013132 (2017).","journal-title":"Pharmacol. Res."},{"key":"1507_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.aan5951","volume":"359","author":"D Miao","year":"2018","unstructured":"Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359, 801\u2013806 (2018).","journal-title":"Science"},{"key":"1507_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.celrep.2012.12.007","volume":"3","author":"C Yang","year":"2013","unstructured":"Yang, C., Huntoon, K., Ksendzovsky, A., Zhuang, Z. & Lonser, R. R. Proteostasis modulators prolong missense VHL protein activity and halt tumor progression. Cell Rep. 3, 52\u201359 (2013).","journal-title":"Cell Rep."},{"key":"1507_CR13","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/hmg\/10.10.1019","volume":"10","author":"MA Hoffman","year":"2001","unstructured":"Hoffman, M. A. et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10, 1019\u20131027 (2001).","journal-title":"Hum. Mol. Genet."},{"key":"1507_CR14","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1093\/hmg\/ddu321","volume":"23","author":"L Gossage","year":"2014","unstructured":"Gossage, L. et al. An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma. Hum. Mol. Genet. 23, 5976\u20135988 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"1507_CR15","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.1021\/pr200642c","volume":"10","author":"Y Lai","year":"2011","unstructured":"Lai, Y., Song, M., Hakala, K., Weintraub, S. T. & Shiio, Y. Proteomic dissection of the von Hippel-Lindau (VHL) interactome. J. Proteome Res. 10, 5175\u20135182 (2011).","journal-title":"J. Proteome Res."},{"key":"1507_CR16","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1073\/pnas.1619726114","volume":"114","author":"W Gao","year":"2017","unstructured":"Gao, W., Li, W., Xiao, T., Liu, X. S. & Kaelin, W. G. Jr. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-\/- clear cell renal carcinoma. Proc. Natl Acad. Sci. USA 114, 1027\u20131032 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1507_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.cell.2007.07.044","volume":"131","author":"A Carbia-Nagashima","year":"2007","unstructured":"Carbia-Nagashima, A. et al. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell 131, 309\u2013323 (2007).","journal-title":"Cell"},{"key":"1507_CR18","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/pro.750","volume":"20","author":"BA Schulman","year":"2011","unstructured":"Schulman, B. A. Twists and turns in ubiquitin-like protein conjugation cascades. Protein Sci. 20, 1941\u20131954 (2011).","journal-title":"Protein Sci."},{"key":"1507_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molcel.2005.03.012","volume":"18","author":"RT Hay","year":"2005","unstructured":"Hay, R. T. SUMO: a history of modification. Mol. Cell 18, 1\u201312 (2005).","journal-title":"Mol. Cell"},{"key":"1507_CR20","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1177\/1535370216651732","volume":"241","author":"A Eisenberg-Lerner","year":"2016","unstructured":"Eisenberg-Lerner, A., Ciechanover, A. & Merbl, Y. Post-translational modification profiling\u2014A novel tool for mapping the protein modification landscape in cancer. Exp. Biol. Med. (Maywood). 241, 1475\u20131482 (2016).","journal-title":"Exp. Biol. Med. (Maywood)."},{"key":"1507_CR21","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1038\/onc.2014.407","volume":"34","author":"J Gerez","year":"2015","unstructured":"Gerez, J. et al. RSUME inhibits VHL and regulates its tumor suppressor function. Oncogene 34, 4855\u20134866 (2015).","journal-title":"Oncogene"},{"key":"1507_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.4067\/S0716-97602009000300012","volume":"42","author":"E Aranda","year":"2009","unstructured":"Aranda, E. & Owen, G. I. A semi-quantitative assay to screen for angiogenic compounds and compounds with angiogenic potential using the EA.hy926 endothelial cell line. Biol. Res. 42, 377\u2013389 (2009).","journal-title":"Biol. Res."},{"key":"1507_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"Cancer-Genome-Atlas-Research-Network.","year":"2013","unstructured":"Cancer-Genome-Atlas-Research-Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43\u201349 (2013).","journal-title":"Nature"},{"key":"1507_CR24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","volume":"23","author":"CJ Ricketts","year":"2018","unstructured":"Ricketts, C. J. et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 23, 313\u2013326 e315 (2018).","journal-title":"Cell Rep."},{"key":"1507_CR25","doi-asserted-by":"crossref","unstructured":"Cai, Q. & Robertson, E. S. Ubiquitin\/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization. PLoS ONE 5, e12636 (2010).","DOI":"10.1371\/journal.pone.0012636"},{"key":"1507_CR26","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10456-018-9613-x","volume":"21","author":"P Nowak-Sliwinska","year":"2018","unstructured":"Nowak-Sliwinska, P. et al. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis 21, 425\u2013532 (2018).","journal-title":"Angiogenesis"},{"key":"1507_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1530\/ERC-11-0211","volume":"19","author":"B Shan","year":"2012","unstructured":"Shan, B. et al. RSUME is implicated in HIF-1-induced VEGF-A production in pituitary tumour cells. Endocr. Relat. Cancer 19, 13\u201327 (2012).","journal-title":"Endocr. Relat. Cancer"},{"key":"1507_CR28","first-page":"1825","volume":"39","author":"CX Ji","year":"2018","unstructured":"Ji, C. X. et al. MicroRNA-375 inhibits glioma cell proliferation and migration by downregulating RWDD3 in vitro. Oncol. Rep. 39, 1825\u20131834 (2018).","journal-title":"Oncol. Rep."},{"key":"1507_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.gene.2016.12.012","volume":"603","author":"W He","year":"2017","unstructured":"He, W. et al. Relationship between RSUME and HIF-1alpha\/VEGF-A with invasion of pituitary adenoma. Gene 603, 54\u201360 (2017).","journal-title":"Gene"},{"key":"1507_CR30","first-page":"384","volume":"16","author":"X Chen","year":"2018","unstructured":"Chen, X. et al. Knockdown of RWD domain containing 3 inhibits the malignant phenotypes of glioblastoma cells via inhibition of phosphoinositide 3-kinase\/protein kinase B signaling. Exp. Ther. Med. 16, 384\u2013393 (2018).","journal-title":"Exp. Ther. Med."},{"key":"1507_CR31","first-page":"298","volume":"128","author":"WG Kaelin Jr.","year":"2017","unstructured":"Kaelin, W. G. Jr. The VHL tumor suppressor gene: Insights into oxygen sensing and cancer. Trans. Am. Clin. Climatol. Assoc. 128, 298\u2013307 (2017).","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"1507_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/srep31128","volume":"6","author":"F Tabaro","year":"2016","unstructured":"Tabaro, F. et al. VHLdb: A database of von Hippel-Lindau protein interactors and mutations. Sci. Rep. 6, 31128 (2016).","journal-title":"Sci. Rep."},{"key":"1507_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2688-0","volume":"16","author":"C Razafinjatovo","year":"2016","unstructured":"Razafinjatovo, C. et al. Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance. BMC Cancer 16, 638 (2016).","journal-title":"BMC Cancer"},{"key":"1507_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.abb.2011.12.023","volume":"518","author":"Y Lai","year":"2012","unstructured":"Lai, Y., Song, M., Hakala, K., Weintraub, S. T. & Shiio, Y. The interaction of the von Hippel-Lindau tumor suppressor and heterochromatin protein 1. Arch. Biochem. Biophys. 518, 103\u2013110 (2012).","journal-title":"Arch. Biochem. Biophys."},{"key":"1507_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.molcel.2007.09.010","volume":"28","author":"H Yang","year":"2007","unstructured":"Yang, H. et al. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol. Cell 28, 15\u201327 (2007).","journal-title":"Mol. Cell"},{"key":"1507_CR36","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.cell.2007.08.045","volume":"131","author":"J Cheng","year":"2007","unstructured":"Cheng, J., Kang, X., Zhang, S. & Yeh, E. T. SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 131, 584\u2013595 (2007).","journal-title":"Cell"},{"key":"1507_CR37","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/0008-5472.CAN-13-2190","volume":"75","author":"MY Koh","year":"2015","unstructured":"Koh, M. Y. et al. Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma. Cancer Res. 75, 316\u2013329 (2015).","journal-title":"Cancer Res."},{"key":"1507_CR38","doi-asserted-by":"publisher","first-page":"e9720","DOI":"10.1371\/journal.pone.0009720","volume":"5","author":"Q Cai","year":"2010","unstructured":"Cai, Q., Verma, S. C., Kumar, P., Ma, M. & Robertson, E. S. Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification. PLoS ONE 5, e9720 (2010).","journal-title":"PLoS ONE"},{"key":"1507_CR39","doi-asserted-by":"publisher","first-page":"e0164554","DOI":"10.1371\/journal.pone.0164554","volume":"11","author":"W Jiang","year":"2016","unstructured":"Jiang, W. et al. Immunohistochemistry successfully uncovers intratumoral heterogeneity and widespread co-losses of chromatin regulators in clear cell renal cell carcinoma. PLoS ONE 11, e0164554 (2016).","journal-title":"PLoS ONE"},{"key":"1507_CR40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/apm.12500","volume":"124","author":"JI Lopez","year":"2016","unstructured":"Lopez, J. I. Intratumor heterogeneity in clear cell renal cell carcinoma: a review for the practicing pathologist. APMIS 124, 153\u2013159 (2016).","journal-title":"APMIS"},{"key":"1507_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2237-x","volume":"16","author":"L Zaldumbide","year":"2016","unstructured":"Zaldumbide, L. et al. Snail heterogeneity in clear cell renal cell carcinoma. BMC Cancer 16, 194 (2016).","journal-title":"BMC Cancer"},{"key":"1507_CR42","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1002\/cncr.24232","volume":"115","author":"WG Kaelin Jr.","year":"2009","unstructured":"Kaelin, W. G. Jr. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 115, 2262\u20132272 (2009).","journal-title":"Cancer"},{"key":"1507_CR43","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1158\/1541-7786.MCR-12-0117","volume":"10","author":"E Jonasch","year":"2012","unstructured":"Jonasch, E. et al. State of the science: an update on renal cell carcinoma. Mol. Cancer Res. 10, 859\u2013880 (2012).","journal-title":"Mol. Cancer Res."},{"key":"1507_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/neup.12316","volume":"37","author":"D Pierscianek","year":"2017","unstructured":"Pierscianek, D. et al. Study of angiogenic signaling pathways in hemangioblastoma. Neuropathology 37, 3\u201311 (2017).","journal-title":"Neuropathology"},{"key":"1507_CR45","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.cell.2014.01.043","volume":"156","author":"DO Croci","year":"2014","unstructured":"Croci, D. O. et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 156, 744\u2013758 (2014).","journal-title":"Cell"},{"key":"1507_CR46","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrd.2016.278","volume":"16","author":"P Saharinen","year":"2017","unstructured":"Saharinen, P., Eklund, L. & Alitalo, K. Therapeutic targeting of the angiopoietin-TIE pathway. Nat. Rev. Drug. Discov. 16, 635\u2013661 (2017).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1507_CR47","doi-asserted-by":"publisher","first-page":"15020","DOI":"10.1038\/mto.2015.20","volume":"2","author":"H Iwamoto","year":"2015","unstructured":"Iwamoto, H. et al. Inhibition of hypoxia-inducible factor via upregulation of von Hippel-Lindau protein induces \u201cangiogenic switch off\u201d in a hepatoma mouse model. Mol. Ther. Oncolytics 2, 15020 (2015).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1507_CR48","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nm0509-491","volume":"15","author":"ML Coleman","year":"2009","unstructured":"Coleman, M. L. & Ratcliffe, P. J. Angiogenesis: escape from hypoxia. Nat. Med. 15, 491\u2013493 (2009).","journal-title":"Nat. Med."},{"key":"1507_CR49","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","volume":"86","author":"D Hanahan","year":"1996","unstructured":"Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353\u2013364 (1996).","journal-title":"Cell"},{"key":"1507_CR50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1023\/A:1026544214667","volume":"19","author":"GL Semenza","year":"2000","unstructured":"Semenza, G. L. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastas-. Rev. 19, 59\u201365 (2000).","journal-title":"Cancer Metastas-. Rev."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1507-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1507-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1507-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T16:42:06Z","timestamp":1671208926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1507-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["1507"],"URL":"https:\/\/doi.org\/10.1038\/s41419-019-1507-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,19]]},"assertion":[{"value":"13 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"266"}}